Based on the sources provided, here is a key summary of the information in bullet points:

### Q3 2025 Financial Performance and Outlook

*   Novartis delivered **solid financial performance in Q3 2025**.
*   **Q3 net sales grew +7%** (constant currencies, cc) to **USD 13.9 billion**. Volume contributed 16 percentage points to growth, partly offset by generic competition (7 percentage points) and pricing (2 percentage points).
*   **Q3 core operating income grew +7% (cc)**. The core operating income margin was stable (cc) at 39.3%.
*   **Q3 operating income grew +27% (cc)**.
*   **Q3 core EPS grew +10% (cc) to USD 2.25**.
*   **Q3 free cash flow was USD 6.2 billion** (+4% USD).
*   The company **reaffirmed its full-year 2025 guidance**. Net sales are expected to grow **high single-digit**, and core operating income is expected to grow **low-teens**.

### Key Growth Drivers (Q3 2025)

*   Sales growth was driven by continued strong execution on priority brands.
*   Top growth drivers based on constant currency growth were:
    *   ***Scemblix*** **(+95% cc)** (USD 358 million).
    *   ***Kisqali*** **(+68% cc)** (USD 1,329 million), driven by strong momentum in the recently launched early breast cancer indication and continued share gains in metastatic breast cancer.
    *   ***Pluvicto*** **(+45% cc)** (USD 564 million), supported by sustained demand growth in the US following the pre-taxane mCRPC approval.
    *   ***Kesimpta*** **(+44% cc)** (USD 1,222 million).
*   ***Entresto*** was the top-selling brand in Q3 2025, with net sales of USD 1,877 million (+1% USD, -1% cc).

### R&D and Pipeline Milestones

*   ***Rhapsido*** **(remibrutinib) received FDA approval** as the only oral, targeted BTK inhibitor for adult patients with chronic spontaneous urticaria (CSU) who remain symptomatic.
*   **Ianalumab** had positive replicate Phase III readouts in Sjogren’s disease, meeting the primary endpoint and demonstrating potential as the first targeted treatment for this chronic autoimmune disease.
*   ***Pluvicto***, in the Phase III PSMAddition trial, reduced the risk of progression or death by 28% versus standard-of-care (SoC) in patients with PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC).
*   ***Scemblix*** received a positive CHMP opinion, recommending granting marketing authorization for all lines of treatment for Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP).
*   ***Cosentyx*** met its primary endpoint in the Phase III REPLENISH study, demonstrating statistically significant and clinically meaningful sustained remission in adults with relapsing polymyalgia rheumatica (PMR).
*   Novartis entered into an agreement to acquire **Tourmaline Bio**, which is developing pacibekitug, a Phase III-ready anti-IL-6 monoclonal antibody for atherosclerotic cardiovascular disease (ASCVD).

### Strategy and Corporate Focus

*   Novartis is a **“pure-play” innovative medicines company**.
*   The company focuses on **four core therapeutic areas:** cardiovascular-renal-metabolic, immunology, neuroscience, and oncology.
*   Investment is prioritized into three emerging technology platforms: **gene & cell therapy, radioligand therapy, and xRNA**.
*   Strategic priorities include accelerating growth (delivering high-value medicines and launch excellence), delivering returns (operational excellence and disciplined capital allocation), and strengthening foundations (scaling data science, technology, and building trust).
*   Novartis aims to make a positive impact by providing access to innovative medicines, protecting the environment, and upholding high ethical standards.
*   Novartis medicines **reach 296 million people worldwide** (or nearly 300 million).

### Capital Structure

*   During the first nine months of 2025, Novartis repurchased 66.4 million shares for **USD 7.5 billion**.
*   Net debt increased to **USD 20.4 billion** at September 30, 2025, up from USD 16.1 billion at the end of 2024. This increase was primarily due to the annual dividend payment, cash outflows for treasury share transactions, and net cash outflow for M&A and intangible assets transactions, which more than offset the free cash flow generated.